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Abstract  
Purpose 
To compare organ specific cancer incidence risks for standard and complex external 
beam radiotherapy including cone beam CT verification following breast conservation 
surgery for early breast cancer.   
Method 
Doses from breast radiotherapy and kilovoltage cone beam CT (CBCT) exposures 
were obtained from thermoluminescent dosimeter (TLD) measurements in an 
anthropomorphic phantom in which the positions of radiosensitive organs were 
delineated. Five treatment deliveries were investigated : (i) conventional tangential 
field whole breast radiotherapy (WBRT), (ii) non-coplanar conformal delivery 
applicable to accelerated partial beast irradiation (APBI), (iii) two-volume 
simultaneous integrated boost (SIB) treatment, (iv) forward planned three-volume 
SIB, (v) inverse-planned three volume SIB. Conformal and intensity modulated 
radiotherapy (IMRT) methods were used to plan the complex treatments. Techniques 
spanned the range from simple methods appropriate for patient cohorts with a low 
local cancer recurrence risk to complex plans relevant to cohorts with high 
recurrence risk. Delineated organs at risk included brain, salivary glands, thyroid, 
contra-lateral breast, left and right lung, oesophagus, stomach, liver, colon and 
bladder. Biological Effects of Ionising Radiation (BEIR) VII cancer incidence models 
were applied to the measured mean organ doses to determine Lifetime Attributable 
Risk (LAR) for ages at exposure from 35 to 80 years according to radiotherapy 
techniques, and included dose from the CBCT imaging.  
Results 
All LAR decreased with age at exposure and were lowest for brain, thyroid, liver and 
bladder (< 0.1%). There was little dependence of LAR on radiotherapy technique for 
these organs and for colon and stomach. LAR values for the lungs for the three SIB 
techniques were two to three times those from WBRT and APBI. Uncertainties in the 
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LAR models outweigh any differences in lung LAR between the SIB methods. 
Constraints in the planning of the SIB methods ensured that contra-lateral breast 
doses and LAR were comparable to WBRT, despite their added complexity. The 
smaller irradiated volume of the ABPI plan contributed to a halving of LAR for contra-
lateral breast compared with the other plan types. Daily image guided radiotherapy 
(IGRT) for a left breast protocol using kilovoltage CBCT contributed <10% to LAR for 
the majority of organs, and did not exceed 22% of total organ dose.  
Conclusion 
Phantom measurements and calculations of LAR from the BEIR VII models predict 
that complex breast radiotherapy techniques do not increase the theoretical risk of 
second cancer incidence for organs distant from the treated breast, or the contra-
lateral breast where appropriate plan constraints are applied. Complex SIB 
treatments are predicted to increase the risk of second cancer incidence in the lungs 
compared to standard whole breast radiotherapy ; this is outweighed by the threefold 
reduction in 5 year local recurrence risk for patients of high risk of recurrence, and 
young age, from the use of radiotherapy. APBI may have a favourable impact on risk 
of second cancer in the contra-lateral breast and lung for older patients at low risk of 
recurrence. Intensive use of IGRT increased the estimated values of LAR but these 
are dominated by the effect of the dose from the radiotherapy, and any increase in 
LAR from IGRT is much lower than the models’ uncertainties.
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I Introduction 
The increasing use of intensity modulated radiotherapy (IMRT), and the associated 
increase in whole body exposure to low doses from scattered and leakage radiation, 
has generated interest on the possible risks of second cancer induction for patients 
receiving curative radiotherapy.1-3 This issue has become of consequence because 
of the success of modern techniques, including radiotherapy, in increasing life 
expectancy for many patients with common cancers. The implications for prostate 
patients have been examined by a number of groups3-6, whilst other have assessed 
the risks to paediatric patients, and patients under 40 years.7-9   
 
Early breast cancer patients have an expectation of good long term survival and 
contribute a large radiotherapy treatment group.10 There has been an increasing use 
of modern methods for the treatment of early breast cancer. Many authors have 
published IMRT techniques for whole breast treatments 11-16 and three clinical trials 
using IMRT have reported dosimetric, medium and long term follow up. 17-20 Baglan et 
al 21 described a method using non-coplanar conformal planning for accelerated 
partial breast irradiation (ABPI) and several groups have reported methods for 
simultaneous integrated boost (SIB) treatments.22-25 The increased complexity of 
these techniques compared to standard whole breast radiotherapy (WBRT), 
potentially increases the dose to non-target tissue. In addition, there is often a need 
to use Image Guided Radiotherapy (IGRT), for example, in partial breast irradiation 
(PBI), or to achieve specific planning target volume (PTV) margins 25.  
 
There has been discussion over the increased use of imaging, and hence dose from 
IGRT systems.26-30. The contributions of IGRT to non-target organ doses have been 
put into context by Harrison et al 28-30 who showed that intense IGRT imaging 
procedures contributed 5 - 30% of the total dose to non-target organs with the 
remainder dose from the radiotherapy scattered and leakage radiation. Harrison et al 
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expressed reluctance to assign risk estimates to their measured organ doses 
although, other groups have found the risk models useful to compare different 
treatment methods whilst accepting the large uncertainties in an absolute risk value. 
31-32
  
 
Given these developments, it is timely that estimates of second cancer incidence risk 
with modern methods are made for the early breast cancer group. We present a set 
of organ doses measured in an anthropomorphic phantom, and estimates of the risk 
of second cancer induction in those organs for five techniques to treat the left breast : 
(i) a conventional tangential field whole breast treatment (WBRT), (ii) a non-coplanar 
conformal delivery applicable to APBI treatment21 , (iii) a two volume SIB, (iv) a three 
volume forward planned SIB (FP SIB) and (v) a three volume inverse planned SIB (IP 
SIB).25 These techniques span the range from simple tangential fields, applicable to 
older patients with a low recurrence risk, to complex techniques, which might be 
appropriate for women with a high recurrence risk (e.g. aged under 50 years). In 
addition, we present measurements in the phantom for an IGRT protocol suitable for 
verifying breast radiotherapy which used kilovoltage cone beam CT (CBCT).  We 
used our data to estimate the risk of second cancer induction in specific organs over 
an age range which reflects the demographic of patients requiring radiotherapy for 
early breast cancer, and put these into the context of recurrence risk from the 
disease. The International Commission on Radiological Protection (ICRP) Report 103 
33
 recommended radiation risk estimates are made for specific organs, thus we have 
based this work on the Biological Effects of Ionising Radiation (BEIR) VII risk models, 
which provide age and sex specific parameters for a range of organs. 34
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II. Methods 
II.A Planning for Standard and Complex Techniques  
A aPhilips Pinnacle3 9.0 system was used to generate the plans which were prepared 
on a CT data set of a patient with left breast disease and tumour bed fiducial 
markers. The simplest technique was a tangential, wedged treatment of the whole 
breast to 40Gy in 15 fractions (the current UK standard dose prescription). The APBI 
treatment was planned as described by Baglan et al21 and prescribed to 38.5Gy in 10 
fractions. It consisted of five non-coplanar fields with wedging and conformal shaping 
to the partial breast PTV using a multileaf collimator (MLC). The method of Hurkmans 
et al 24 was used to plan the two volume SIB treatment which was prescribed to 51.5 
Gy to whole breast and 74 Gy to the tumour bed in 31 fractions. Two IMRT fields 
were used to treat the whole breast and three conformal fields used to treat the 
tumour bed PTV. Beam weight optimisation was applied to these latter beams. The 
most complex treatment was a three volume SIB IMRT plan designed to deliver 36Gy 
to whole breast, 40Gy to partial breast and 53Gy to the tumour bed in 15 fractions.25 
The plan consisted of tangential fields to cover the whole breast, plus 5 co-planar 
fields to deliver the dose to the partial breast and the tumour bed PTV. Beam 
weights, segment weights and MLC shaping were designed using both forward or 
inverse planning approaches as described by Donovan et al. 35 Sagittal dose 
distributions are shown in Figure 1. The 2Gy equivalent dose (EQD2) for each 
fractionation regimen is given in Table 1 assuming an βα /  ratio of 3 for tumour 
control36. 
 
II.B  Measurement of Treatment Doses in an Anthropomorphic Phantom 
The plans were transferred to a CT scan of a Rando anthropomorphic phantom 
which had semi-realistic breast attachments added. An experienced clinician (MB) 
                                                 
a
 Philips Medical Systems, Palo Alto, US 
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outlined regions representative of radiosensitive organs : brain, salivary glands, 
thyroid, left and right breast, left and right lung, oesophagus, stomach, liver, colon 
and bladder. Harshaw TLD-100 (LiF:Ti, Mg) thermoluminescent dosimeters (TLD) 
were placed uniformly within the positions of the outlined organs from slice 1 (head) 
to slice 33 (base of pelvis). Table 1 gives the number of TLD in each region. Each 
TLD was uniquely identified and the dose calculated as given in equation 1.   
( )
calchipBkgTLDTLD xCFxCFRRDose −=                                 (1) 
where RTLD = TLD output in nC, RBkg = unirradiated TLD output in nC, CFchip = 
individual chip factor, to account for the variability of chip output within the batch, 
CFcal = calibration factor  to convert from nC to Gy. CFcal was derived from a 
calibration curve produced by irradiating sets of 10 TLD in water equivalent material 
to doses between 0.02 and 8.5Gy respectively in a 6MV beam. One set was left un-
irradiated to provide a background signal. The calibration was confirmed with a 
repeat set of measurements. The difference in calibration factor was 0.6%.The output 
and linearity of the linear accelerator were confirmed prior to irradiation with an 
ionisation chamber and electrometer with a calibration traceable to the MV national 
standard37. The TLD were read out using a bHarshaw 5500 reader and annealed 
using a standard of 4000C for 90 minutes, 800C for 960 minutes followed by free 
cooling to air temperature. The time interval between irradiation and readout was 14 
hours for calibration and experimental sessions; this minimised any error due to 
fading. Five fractions were delivered to the phantom for each technique at the 
measurement session, and the data scaled to give the total dose in Gy for the 
complete treatment. All plans were delivered with an cElekta Synergy linear 
accelerator at 6MV photon beam energy. 
 
II.C Measurement of Cone Beam CT Doses in an Anthropomorphic Phantom  
                                                 
 
b
 Thermo Fisher Scientific Inc., Erlangen, Germany 
c
 Elekta Oncology Systems, Crawley, UK 
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The CBCT exposures were delivered with an Elekta XVI system, which is integrated 
on the linac gantry with the kV tube at 90O to the treatment head. 10 exposures were 
made in the measurement session to ensure sufficient dose to the TLD. The left 
breast imaging protocol consisted of a scan arc of 185O with a gantry start angle of 
260O (kV start angle 350O) and gantry stop angle of 85O (kV stop angle 175O)38. A 
100kVp generating potential was set with parameters of 25mA, 40ms and 361 
imaging frames. A S20 collimator (= 26 cm reconstruction circle) was used with no 
beam shaping filter. TLD were calibrated at 100kVp using a Gulmay orthovoltage unit 
and a dose calibration traceable to the UK kilovoltage primary standard.39 
  
II.D Second Cancer Risk Model 
Several risk models have been developed to estimate cancer incidence and 
mortality: ICRP 33, BEIR 34, United Nations Scientific Committee on the Effects of 
Atomic Radiation (UNSCEAR)40.  The uncertainties associated with each of the 
models are close to, or exceed, the variation between the models32. We have chosen 
to use the BEIR VII model as it provides model parameters for specific organs for 
each sex and includes a parameter describing incidence with age at exposure and 
attained age. Our focus was to estimate cancer incidence over an age range of 35 to 
80 years (which reflects the typical age distribution of breast cancer incidence in 
Europe and the US).   
 
We have evaluated Lifetime Attributable Risk (LAR) via the method given in the BEIR 
VII report, with a slight modification to sum to age 90. This summation gave 
consistency with the data from ICRP Report 10333, which is required in the 
calculation of LAR, but is not stratified above age 90 years.   Equation 2 is the BEIR 
committee recommended model for both Excess Relative Risk (ERR) and Excess 
Absolute Risk (EAR). 
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ERR and EAR = ηγβ )
60
*)(exp( aeDS              (2)  
 
where D = dose; βS, γ and η are ERR and EAR specific parameters for various 
organs for each sex; e is age at exposure; e*= (e-30)/10 for e<30 and 0 for e>30 
years; a is attained age.  
For organs other than breast, lung and thyroid the BEIR VII report recommends 
calculating Lifetime Attributable Risk (LAR) as given in equation 3. 
LAR (D,e) = ∑∑
90
3.07.0
90
))(/)().,,(())(/)(.).,,((
aa
C
I daeSaSaeDEARxdaeSaSaeDERR λ (3) 
ERR (D,e,a,) and EAR (D,e,a) are described by equation 2; CIλ represents the baseline 
cancer risk and data were taken from ICRP Report 103; ). S(a)/S(e) is the probability 
of surviving to the attained age (a) conditional on survival to exposed age (e) and 
was derived from the life span tables of the UK Office for National Statistics 2006-
2008.41  The functions are summed from a=e+L to 90 years, with e = age at exposure 
and L = latency period (5 years for solid cancer). The weights 0.7 and 0.3 are 
recommended by the BEIR Committee for most organs. They reflect the greater 
support for relative risk transport between populations rather than absolute risk.  
The weights of 0.7 and 0.3 are reversed for lung; for breast only the EAR model is 
recommended (from the work of Preston et al 42) and for thyroid there is no EAR 
model and LAR is calculated using the ERR model only. There were no model 
parameters given for the salivary glands.  Hall et al 2,and Pierce et al 43show data 
from the atomic bomb survivors which indicates that risk is linear with dose over the 
range from 0.1 to 2.5 Gy. The BEIR VII report used the linear no-threshold model. 
Linear scaling has been used to calculate LAR for the mean organ doses presented 
in this work. A dose and dose-rate effective factor (DDREF) of 1.5, as recommended 
in the BEIR VII report, was applied to the calculated LAR. 
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III Results 
III.A Measured Organ Doses  
Table 1 shows the mean dose per organ from the radiotherapy deliveries and the 
total for 15 CBCT imaging exposures. The data are stratified into three dose levels 
<0.5Gy; ≥ 0.5 and < 1.0Gy; ≥ 1.0Gy. These data are expressed as a percentage of 
maximum prescribed dose in Table 2. Table 3 expresses the CBCT organ doses as a 
percentage of total (radiotherapy plus imaging) doses assuming online verification of 
each treatment fraction for each schedule. The mean background output of the TLD 
was 0.1nC± 0.03nC; the lowest TLD output from an irradiation session was 1.2nC. 
The uncertainties in the measured dose from individual TLDs ranged from 2.5% to 
6.5%, with a median of 3.4% at 6MV; 2.4% to 6.1% with a median of 2.8% at 
100kVp. These quoted uncertainties were based on a standard uncertainty multiplied 
by a coverage factor k = 2, providing a level of confidence of approximately 95%. 
 
The pattern in the dose data was as expected. Distant organs (brain, salivary glands, 
thyroid, colon, bladder) received mean doses less than 0.2Gy with higher doses 
close to the treated region. Organs received the lowest doses from the APBI 
techniques because of the smaller volume irradiated and lower prescribed dose. The 
three complex SIB techniques delivered higher doses to more organs than the 
standard whole breast method. The main difference between the SIB techniques was 
in the mean contra-lateral lung and oesophagus doses. Whilst doses from the CBCT 
imaging were low compared to these from the radiotherapy, they contributed 10% to 
20% of total organ dose in some cases (Table 3). 
 
III.B Lifetime Attributable Risk 
The uncertainties in estimated LAR based on the models presented in the BEIR VII 
report34 are high. The authors comment, in their analysis of LAR uncertainty, that this 
is dominated by the uncertainty in the estimated value of the model parameter β in 
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the models of ERR and EAR.  The report gives an estimate of LAR for solid cancer 
incidence in the female breast as 310 cases (95% confidence intervals (CI) 160, 610) 
per 100,000 of mixed age exposed to 0.1Gy. For lung cancer incidence in females of 
the same population and dose, LAR is given as 300 (95% CI 120, 780). Other sites 
have similar levels of uncertainty.  
 
LAR data for all radiotherapy techniques from age at exposure of 35 to 90 years for 
each measured organ are given in Tables 4 and 5 and assumed to have uncertainty 
levels as discussed. The data were separated by class of plan. Whole breast and 
ABPI were considered as applicable to patients with low recurrence risk (Table 4); 
the SIB methods appropriate for cohorts with high recurrence risk (Table 5). The LAR 
data show the strong age dependency of the cancer incidence risk in the BEIR VII 
model. This is pronounced in the breast data where there is a 60 fold decrease in 
LAR from age at exposure of 35 years to that at 80 years; the decrease is 5 to 10 fold 
for other organs. The variation in the magnitude of the LAR data follows the pattern 
of the measured doses.  
 
Data for all techniques, plus that from daily IGRT,  for age at exposure of 40 and 60 
years are taken from Tables 4 and 5 and presented graphically in Figure 2 (a) and 
(b). These ages represent younger women, who would be at a higher risk of 
recurrence at the time of diagnosis, and older women with a lower risk. The LAR 
values are dominated by the radiotherapy contribution to total dose. The LAR values 
are lowest for brain, thyroid, liver and bladder and there is little impact from 
radiotherapy technique observed in the data for these organs, or the colon and 
stomach. The uncertainties in the LAR model outweigh any differences in the risk to 
the lungs from the three SIB methods. However the LAR for the three SIB techniques 
is 2 -3 times that from the whole breast RT and APBI deliveries. Constraints in the 
planning of the SIB methods meant that contra-lateral breast doses, were of a similar 
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order to a whole breast plan despite the complexity of the SIB plans. This is reflected 
in the LAR values. The consequence of the smaller irradiated volume of the ABPI 
plan is seen in the lower magnitude of LAR for contra-lateral breast compared with 
the other four plan types. 
 
Figure 3 places the calculated LAR for the techniques in the context of the local 
recurrence risk estimates (with and without radiotherapy) from the Early Breast 
Cancer Trialists’ Collaborative Group (EBCTCG) 2005 overview10. EBCTCG data 
show an increase in lung and contra-lateral breast second cancers following 
radiotherapy; LAR for these at risk organs is plotted in Figure 3. The data and 
techniques are separated as for Tables 4 and 5. For the specific plans and 
equipment used in this work, LAR are predicted to be low for all techniques 
compared to the gain from radiotherapy which reduces 5 year recurrence from 33% 
to 11% for a cohort of 40 year old women, and from 11% to 4% for a population of 60 
year old women.
 13 
IV Discussion 
We have described measured out-of-field doses, and presented estimated LAR for 
cancer incidence, for standard whole breast and four complex breast treatments over 
a range of organs delineated in an anthropomorphic phantom. The data have been 
used to assess the change in risk of second cancer incidence for complex deliveries 
compared to standard whole breast radiotherapy.  
The analysis of the EBCTCG 10 shows both lung and contra-lateral breast second 
cancer incidence increased with the use of radiotherapy. Figure 3 shows our 
estimates of LAR for these organs, with an example of a risk from the disease (the 5 
year local recurrence rate), in order to give the risks from treatment (which includes 
the CBCT imaging) a relevant context. More complex techniques are likely to be 
used either where there is complex anatomy making standard planning difficult, or in 
patients at higher risk of disease recurrence. As younger age is a risk factor for 
recurrence we have compared the SIB treatments to recurrence risk for a 40 year old 
woman in Figure 3 (a). Technical solutions for older patients may be simpler, or 
irradiate only part of the breast, and deliver lower dose to non-target regions. The 
whole breast and APBI treatments have been compared with recurrence risk for a 60 
year old woman in Figure 3(b). The balance between disease risk and treatment risk 
will change if recurrence rates fall and/or complex deliveries increase doses such 
that LAR values approach the recurrence rates. Mannino and Yarnold et al present 
data which indicates recurrence rates have reduced.44 Only cancer induction has 
been considered as a treatment risk in this work; it is noted that other damage from 
radiotherapy is relevant e.g. the risk of cardiac morbidity, lung fibrosis and damage to 
the oesophagus. 
 
The effect of measured dose from the intensive use of IGRT with CBCT on the total 
LAR for cancer incidence was shown to be small relative to the impact of the 
radiotherapy. The values of LAR from the radiotherapy and the uncertainty 
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associated with the estimates indicate that a large change in the magnitude of the 
CBCT dose may be made (e.g. doubling or halving the dose) without affecting the 
estimated risk. It is a requirement, and good practice, to have a protocol appropriate 
for the task to limit unnecessary organ exposure. The one used in this work used a 
180O scan to minimise contra-lateral organ dose.   Whilst this work indicates that daily 
online imaging for breast cancer patients does not significantly increase the predicted 
cancer incidence risk, correction strategies which limit the concomitant dose but still 
reduce the systematic and random set up errors should be considered45. The dose 
burden of IGRT should be weighed against the useful information in the image, e.g. 
Harris et al 46 have tracked the distortion of tumour beds over a treatment course. 
This may require a higher imaging dose but is justified by the increase in 
understanding and improvement to treatment accuracy. 
 
Trials of advanced methods, for example, the US Accelerated Partial Breast 
Irradiation (APBI) trials 47 , the Netherlands boost trial48 and the UK Intensity 
Modulated and Partial Organ Radiotherapy (IMPORT) High trial 25 have detailed 
specifications for target and organ at risk doses. The strong age dependency in the 
data which forms the basis of the BEIR VII model, indicate that it may be appropriate 
to stratify the trial constraints further based on age, for example, for the contra-lateral 
breast. The risk of recurrence in the younger age group is higher than that for older 
women (Figure 3), and control of primary disease may be of greater importance than 
a theoretical increase in cancer induction risk when assessing the merits of different 
types of treatment deliveries.  
 
There is much interest in hypofractionated and accelerated schedules for early breast 
cancer. These result in lower total physical doses, for example, the UK Faster 
Radiotherapy for Breast Cancer patients (FAST) trial of 30Gy in 5 fractions 49 and the 
US APBI study of 38.5Gy in 10 fractions. 333 The BEIR VII models do not include a 
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term for dose per fraction per organ, only total dose, hence the use of the models 
predicts a decrease in second cancer risk for some organs even if sophisticated 
techniques are needed for radiotherapy delivery. 
 
Data to improve the risk estimates will only be obtained by good mapping of both 
recurrences and new primaries against RT dose distributions and the out-of-field 
doses. We suggest clinical trials testing new RT techniques could, as part of the pre-
trial QA,  incorporate the measurement of anthropomorphic phantom whole body 
doses or use MC simulation of out-of-field doses if available. Whilst this would not 
inform on a per patient basis, it would give useful information about relative changes 
in dose in the regions outside of the RT CT planning scan. The nature of these doses 
is that they do not need to be known to the level of accuracy of those within the 
region covered by the CT scan, hence the inevitably larger measurement errors 
would not outweigh the usefulness. Our data in Tables 1and 2 shows differences in 
technique are observed by doing this. This information and the detailed dosimetry of 
the treatment region could be used in combination with the epidemiological studies to 
help improve the risk models. The era of good quality and widely available imaging 
should allow this mapping.
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V Conclusions 
 
The dose measurements and calculations of LAR presented indicate that more 
sophisticated methods for breast radiotherapy do not increase the theoretical risk of 
second cancer incidence for organs distant from the treated breast. Complex SIB 
treatments are predicted to increase the risk of second cancer in the lungs compared 
to standard whole breast radiotherapy, however, this is outweighed by the threefold 
reduction in 5 year local recurrence risk for patients of high risk of recurrence and 
young age. If dose constraints for the contra-lateral breast are set so that they do not 
exceed those of standard tangents, then complex methods do not increase LAR, 
although age specific contra-lateral breast dose constraints could be considered in 
clinical trials of breast radiotherapy. APBI may have a favourable impact on risk of 
second cancer in the contra-lateral breast for older patients at low risk of recurrence. 
Intensive use of IGRT theoretically increases the estimated values of LAR but these 
are dominated by the effect of the dose from the radiotherapy, and any increase in 
LAR from IGRT is much lower than the uncertainty in the models. Whilst appropriate 
imaging protocols should be used, daily imaging using CBCT of patients at high risk 
of recurrence receiving complex radiotherapy is unlikely on its own to result in an 
unacceptable increase in the risk of second cancer.  
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Figure 1 Sagittal dose distributions 
                
 (a) Whole breast (WBRT)   (b)    APBI 
                
      
(c) Two volume SIB    (d)   Three volume SIB FP IMRT 
 
 
 
(e)  Three volume SIB IP IMRT 
 
Purple represents the whole breast 
planning target volume (PTV); green 
represents the partial breast PTV;  
blue represents the tumour bed PTV. 
95% isodoses at each dose level are 
represented in yellow, 100% isodoses 
in red and 107% isodoses in bright 
green. 
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 Figure 2 : LAR for age at exposure of (a ) 40 and  (b) 60 years for all measured  
organs, all treatment deliveries and assuming daily CBCT imaging. 
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Figure 3 (a) and (b) Recurrence risks and estimated treatment risks 
(radiotherapy and intensive CBCT imaging) at for population of 40 and 60 
years.  
Data on recurrence from Early Breast Trialists’ Collaborative Group10.  
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Table 1 Measured Mean Organ Doses in Phantom (Gy) 
Organ Number 
of TLD WBRT 
APBI 
 
SIB 
2 volumes 
 
SIB 
3 volumes 
FP IMRT 
SIB 
3 volumes 
IP IMRT 
 Cone beam 
CT 
Imaging 
 
 
40 Gy  
whole breast 
15 fractions 
 
*EQD2 = 46 Gy 
38.5 Gy  
partial breast 
10 fractions 
 
+EQD2 = 65 Gy 
51.5 Gy whole breast 
74 Gy tumour bed 
31 fractions 
 
EQD2 = 48Gy & 79Gy 
36 Gy whole breast 
40 Gy partial breast 
53 Gy tumour bed 
15 fractions 
EQD2 = 40Gy 46Gy & 69Gy 
 
15 imaging 
exposures 
Brain 25 0.05 0.04 0.07 0.06 0.07  0.001 
Salivary glands 2 0.08 0.06 0.12 0.10 0.08  0.003 
Thyroid 2 0.10 0.09 0.16 0.13 0.12  0.01 
Contra-lateral 
breast 20 0.59 0.19 0.72 0.63 1.14 
 0.03 
Ipsi-lateral Lung 39 0.69 0.70 1.92 1.34 1.79  0.06 
Contra-lateral lung 39 0.11 0.07 1.05 0.28 0.64  0.02 
Oesophagus 8 0.13 0.10 2.05 0.39 0.61  0.03 
Liver 41 0.15 0.19 0.26 0.16 0.25  0.03 
Stomach 13 0.70 0.25 0.68 0.61 0.62  0.08 
Colon 20 0.09 0.07 0.12 0.19 0.09  0.01 
Bladder 5 0.02 0.02 0.03 0.03 0.02  0.004 
Data highlighted in dark grey ≥ 1 Gy; data highlighted in grey ≥ 0.5 Gy and <1.0Gy; other data < 0.5Gy.  *EDQ2 is Equivalent dose in 2Gy fraction 
size. Calculations assume βα /  = 336.      +Incomplete repair with t1/2 = 4.4 hours. 
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Table 2 Mean organ dose as a percentage of maximum prescribed dose (%) 
Organ WBRT APBI 
 
SIB 
2 volumes 
 
SIB 
3 volumes 
FP IMRT 
SIB 
3 volumes 
IP IMRT 
Brain 0.1 0.1 0.1 0.1 0.1 
Salivary glands 0.2 0.2 0.2 0.2 0.2 
Thyroid 0.3 0.2 0.2 0.2 0.2 
Contra-lateral 
breast 1.5 0.5 1.0 1.2 2.2 
Ipsi-lateral Lung 1.7 1.8 2.6 2.5 3.4 
Contra-lateral 
lung 0.3 0.2 1.4 0.5 1.2 
 
Oesophagus 0.3 0.3 2.8 0.7 1.2 
Liver 0.4 0.5 0.4 0.3 0.5 
Stomach 1.8 0.6 0.9 1.2 1.2 
Colon 0.2 0.2 0.2 0.4 0.2 
Bladder 0.1 0.1 0.1 0.1 0.1 
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Table 3  
Cone beam CT organ dose as a percentage of total organ dose from radiotherapy and imaging 
(%). Left breast treatment and imaging. 
Data assumes online verification of all treatment fractions for each technique and prescription. 
Organ WBRT APBI 
 
SIB 
2 volumes 
 
SIB 
3 volumes 
FP IMRT 
SIB 
3 volumes 
IP IMRT 
 
15 imaging 
exposures 
10 imaging 
exposures 
31 imaging 
exposures 
15 imaging 
exposures 
15 imaging 
exposures 
Brain 
 2.1 1.6 2.8 1.6 1.4 
Salivary glands 3.6 3.2 4.9 2.9 3.6 
Thyroid 9.1 6.7 11.5 7.1 7.7 
Contra-lateral 
breast 4.8 9.1 7.9 4.5 2.6 
Ipsi-lateral Lung 8.0 5.3 6.1 4.3 3.2 
Contra-lateral 
lung 15.4 14.8 3.8 6.7 3.0 
 
Oesophagus 18.8 15.4 2.9 7.1 4.7 
Liver 16.7 9.1 19.3 15.8 10.7 
Stomach 10.3 16.2 19.6 11.6 11.4 
Colon 10.0 8.3 14.7 5.0 10.0 
Bladder 16.7 11.1 21.6 11.8 16.7 
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Table 4  
LAR data for all organs and ages at exposure summed to 90 years :  
WBRT and APBI techniques (no boost) 
  LAR (cancer incidence per 100 000 population) 
  Age at Exposure 
Organ Technique 35 40 50 60 70 80 
Brain WBRT 17 15 12 9 5 2 
 APBI 13 12 9 7 4 2 
Thyroid WBRT 28 23 21 18 13 5 
 APBI 25 21 19 16 12 5 
Contra-lateral lung WBRT 116 114 108 93 63 24 
 APBI 74 73 69 59 40 15 
Contra-lateral breast WBRT 566 425 218 97 35 9 
 APBI 182 137 70 31 11 3 
Oesophagus WBRT 27 26 23 18 12 4 
 APBI 21 20 18 14 9 3 
Liver WBRT 17 15 15 12 8 2 
 APBI 21 19 19 15 10 2 
Stomach WBRT 294 287 266 224 161 63 
 APBI 105 103 95 80 58 23 
Colon WBRT 65 63 59 49 32 12 
 APBI 50 49 46 38 25 9 
Bladder WBRT 8 8 8 6 5 2 
 APBI 8 8 8 6 5 2 
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Table 5  
LAR data for all organs and ages at exposure summed to 90 years :  
Simultaneous Integrated Boost techniques  
  LAR (cancer incidence per 100 000 population) 
  Age at Exposure 
Organ Technique 35 40 50 60 70 80 
Brain SIB 2 volume  23 20 16 12 7 3 
 SIB 3 volume FP IMRT 20 17 14 10 6 2 
 SIB 3 volume IP IMRT 23 20 16 12 7 3 
Thyroid SIB 2 volume  45 37 34 29 21 8 
 SIB 3 volume FP IMRT 36 30 27 23 17 7 
 SIB 3 volume IP IMRT 34 28 25 22 16 6 
Contra-lateral lung SIB 2 volume  1108 1092 1034 887 599 226 
 SIB 3 volume FP IMRT 295 291 276 237 160 60 
 SIB 3 volume IP IMRT 675 666 630 541 365 138 
Contra-lateral breast SIB 2 volume  691 518 266 119 43 11 
 SIB 3 volume FP IMRT 605 454 233 104 38 9 
 SIB 3 volume IP IMRT 1094 821 422 188 68 17 
Oesophagus SIB 2 volume  431 410 369 287 185 62 
 SIB 3 volume FP IMRT 82 78 70 55 35 12 
 SIB 3 volume IP IMRT 128 122 110 85 55 18 
Liver SIB 2 volume  29 26 26 21 13 3 
 SIB 3 volume FP IMRT 18 16 16 13 8 2 
 SIB 3 volume IP IMRT 28 25 25 20 13 3 
Stomach SIB 2 volume  286 279 258 218 156 61 
 SIB 3 volume FP IMRT 256 250 232 195 140 55 
 SIB 3 volume IP IMRT 260 254 236 198 143 56 
Colon SIB 2 volume  86 49 46 38 25 9 
 SIB 3 volume FP IMRT 137 133 124 103 68 25 
 SIB 3 volume IP IMRT 65 63 59 49 32 12 
Bladder SIB 2 volume  13 12 11 10 7 3 
 SIB 3 volume FP IMRT 13 12 11 10 7 3 
 
